Is high-sensitivity C-reactive protein associated with subclinical peripheral atherosclerosis?

Angiology

Volumn 60, Issue 1, 2009, Pages 8-11

  Paraskevas, Kosmas I ^a   Bessias, Nikolaos ^b   Papas, Theofanis T ^a   Andrikopoulos, Vassilios ^a   Mikhailidis, Dimitri P ^b,c  

^a RED CROSS HOSPITAL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CONNECTIVE TISSUE DISEASE; ENTERITIS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INFECTION; NEOPLASM; NOTE; OBESITY; PREGNANCY; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 59149085944     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708330707     Document Type: Note

References (48)

1. Bo M., Corsinovi L., Brescianini A., et al. High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis. Angiology. 2009 ; IN PRESS.
2. Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003 ; 107: 363-369.
3. Paffen E., DeMaat MP C-reactive protein in atherosclerosis: a causal factor ? Cardiovasc Res. 2006 ; 71: 30-39.
4. Miller VM, Redfield MM, McConnell JP Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol. 2007 ; 5: 15-25.
5. Ridker PM, Cushman M., Stampfer MJ, Tracy RP, Hennekens CH Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998 ; 97: 425-428.
6. Shankar A., Li J., Nieto FJ, Klein BE, Klein R. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007 ; 154: 495-501.
7. Wildman RP, Muntner P., Chen J., et al. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005 ; 96: 1579-1583.
8. Vu JD, Vu JB, Pio JR, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005 ; 96: 655-658.
9. Hozawa A., Ohmori K., Kuriyama S., et al. C-reactive protein and peripheral artery disease among Japanese elderly: the Tsurugaya Project. Hypertens Res. 2004 ; 27: 955-961.
10. Daskalopoulou SS, Pathmarajah M., Kakkos SK, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J. 2008 ; 72: 441-448.
11. Hulthe J., Wikstrand J., Fageberg B. Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study. Clin Sci (Lond). 2001 ; 100: 371-378.
12. Khera A., de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation. 2006 ; 113: 38-43.
13. Vainas T., Stassen FR, de Graaf R., et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and future cardiovascular events. J Vasc Surg. 2005 ; 42: 243-251.
14. Tzoulaki I., Murray GD, Lee AJ, Rumley A., Lowe GD, Fowkes FG C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 2005 ; 112: 976-983.
15. Van Der Meer IM, De Maat MP, Hak AE, et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke. 2002 ; 33: 2750-2755.
16. Owens CD, Ridker PM, Belkin M., et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg. 2007 ; 45: 2-9.
17. Fatourou EM, Paraskevas KI, Seifalian AM, Hamilton G., Mikhailidis DP The role of established and emerging risk factors in peripheral vascular graft occlusion. Expert Opin Pharmacother. 2007 ; 8: 901-911.
18. Abdellaoui A., Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007 ; 34: 18-22.
19. Li JJ, Fang CH, Jiang H., et al. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology. 2004 ; 55: 479-484.
20. Barutcu I., Sezgin AT, Sezgin N., et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology. 2007 ; 58: 401-407.
21. Oren H., Erbay AR, Balci M., et al. Role of novel biomarkers of inflammation in patients with stable coronary heart disease. Angiology. 2007 ; 58: 148-155.
22. Oren H., Erbay AR, Balci M., Cehreli S. Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients ? Angiology. 2007 ; 58: 45-54.
23. Liang YJ, Shyu KG, Wang BW, et al. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology. 2008 ; 110: 182-190.
24. Asher J., Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich). 2007 ; 9: 622-628.
25. Efthimiadis A. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises? Angiology. 2008 ; 59 (2 Suppl). 62S - 64S.
26. Schillinger M., Exner M., Mlekusch W., et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004 ; 25: 742-748.
27. Tsiara S., Elisaf M., Mikhailidis DP Early vascular benefits of statin therapy. Curr Med Res Opin. 2003 ; 19: 540-556.
28. Milionis HJ, Rizos E., Kostapanos M., et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006 ; 22: 1123-1131.
29. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem. 2005 ; 12: 443-452.
30. Alnaeb ME, Alobaid N., Seifalian AM, Mikhailidis DP, Hamilton G. Statins and peripheral arterial disease: potential mechanisms and clinical benefits. Ann Vasc Surg. 2006 ; 20: 696-705.
31. Isma N., Barani J., Mattiason I., Lindblad B., Gottsater A. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia. Angiology. 2008 ; 59: 542-548.
32. Paraskevas KI, Mikhailidis DP C-reactive protein (CRP): more than just an innocent bystander ? Curr Med Res Opin. 2008 ; 24: 75-78.
33. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol. 2008 ; 6: 258-270.
34. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein-E deficient mice. Proc Natl Acad Sci USA. 2005 ; 102: 8309-8314.
35. Tennent GA, Hutchinson WL, Kahan MC, et al. Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice. Atherosclerosis. 2008 ; 196: 248-255.
36. Lowe GD, Pepys MB C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep. 2006 ; 8: 421-428.
37. Pitsavos C., Panagiotakos DB, Tzima N., et al. Diet, exercise and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological study. Angiology. 2007 ; 58: 225-233.
38. Pepys MB CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1091-1094.
39. Suckling K. The continuing complexes of high-density lipoprotein metabolism in drug discovery and development. Expert Opin Ther Targets. 2007 ; 11: 1133-1136.
40. Ludwig RJ, Schon MP, Boehncke WH P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets. 2007 ; 11: 1103-1117.
41. Tziomalos K., Athyros VG, Karagiannis A., et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets. 2007 ; 11: 1143-1160.
42. Salh B. c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin Ther Targets. 2007 ; 11: 1139-1153.
43. Jeyaseelan K., Herath WB, Armugam A. MicroRNAs as therapeutic targets in human diseases. Expert Opin Ther Targets. 2007 ; 11: 1119-1129.
44. Paraskevas KI, Psathas C., Dragios T., et al. The impact of novel treatment modalities on the therapeutic approach of cardiovascular diseases. Angiology. 2009 ; IN PRESS.
45. Ridker CM, Cannon CP, Morrow D., et al, and the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein and outcomes after statin therapy. N Engl J Med. 2005 ; 352: 20-28.
46. Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 ; 359: 2195-2207.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
48. Tziomalos K., Athyros VG, Karagiannis A., Mikhailidis DP JUPITER: major implications for vascular risk assessment. Curr Med Res Opin. 2009 ; IN PRESS.